Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 14Terminated 9Recruiting 7Active not recruiting 7Unknown 3Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Neoplasm Metastasis 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Resectable Pancreatic Cancer 1Recurrent Bladder Urothelial Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × 130-nm albumin-bound paclitaxel × Clear all
NCT05653661 2025-01-07

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Mayo Clinic

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT02300935 2019-05-30

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

SCRI Development Innovations, LLC

Phase 1 Withdrawn
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡